144 related articles for article (PubMed ID: 38242556)
1. Clinicopathological features of kidney injury in patients receiving immune checkpoint inhibitors (ICPi) combined with anti-vascular endothelial growth factor (anti-VEGF) therapy.
Jin S; Shen Z; Li J; Liu X; Zhu Q; Li F; Shi Y; Lin P; Xu X; Chen X; Geng X; Ding X; Liu H
J Clin Pathol; 2024 Jun; 77(7):471-477. PubMed ID: 38242556
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
3. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
[TBL] [Abstract][Full Text] [Related]
4. Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study.
Zhu J; Ding X; Zhang J; Chen B; You X; Chen X; Chen T
BMC Cancer; 2024 Jun; 24(1):756. PubMed ID: 38914959
[TBL] [Abstract][Full Text] [Related]
5. Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity.
Liu Q; Yu Y; Lin J; Wang Y; Ai L; Li Q; Wu W; Jin H; Li S; Liu M; Yu S; Liu T
Eur J Cancer; 2021 Nov; 157():10-20. PubMed ID: 34464781
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis.
Kanbay M; Yildiz AB; Siriopol D; Vehbi S; Hasbal NB; Kesgin YE; Celayir M; Selcukbiricik F; Covic A; Perazella MA
Int Urol Nephrol; 2023 Apr; 55(4):1025-1032. PubMed ID: 36282399
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020.
Gupta S; Cortazar FB; Riella LV; Leaf DE
Kidney360; 2020 Feb; 1(2):130-140. PubMed ID: 35372904
[TBL] [Abstract][Full Text] [Related]
8. Pathologic Correlation with Renal Dysfunction after Intravitreal Injections of Vascular Endothelial Growth Factor Antagonists.
Zhang PL; Raza S; Li W; Kanaan HD
Ann Clin Lab Sci; 2021 Nov; 51(6):875-882. PubMed ID: 34921042
[TBL] [Abstract][Full Text] [Related]
9. Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study.
Lumlertgul N; Vassallo P; Tydeman F; Lewis N; Hobill A; Weerapolchai K; Nordin NZ; Seylanova N; Martin L; Cennamo A; Wang Y; Rigg A; Shaunak N; Ostermann M
Eur J Cancer; 2023 Sep; 191():112967. PubMed ID: 37499561
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal Antivascular Endothelial Growth Factor Therapy May Induce Proteinuria and Antibody Mediated Injury in Renal Allografts.
Cheungpasitporn W; Chebib FT; Cornell LD; Brodin ML; Nasr SH; Schinstock CA; Stegall MD; Amer H
Transplantation; 2015 Nov; 99(11):2382-6. PubMed ID: 25905984
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.
Albiges L; McGregor BA; Heng DYC; Procopio G; de Velasco G; Taguieva-Pioger N; Martín-Couce L; Tannir NM; Powles T
Cancer Treat Rev; 2024 Jan; 122():102652. PubMed ID: 37980876
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC
Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study.
Shimamura Y; Watanabe S; Maeda T; Abe K; Ogawa Y; Takizawa H
Clin Exp Nephrol; 2021 May; 25(5):479-487. PubMed ID: 33471239
[TBL] [Abstract][Full Text] [Related]
14. Acute kidney injury in patients treated with immune checkpoint inhibitors.
Gupta S; Short SAP; Sise ME; Prosek JM; Madhavan SM; Soler MJ; Ostermann M; Herrmann SM; Abudayyeh A; Anand S; Glezerman I; Motwani SS; Murakami N; Wanchoo R; Ortiz-Melo DI; Rashidi A; Sprangers B; Aggarwal V; Malik AB; Loew S; Carlos CA; Chang WT; Beckerman P; Mithani Z; Shah CV; Renaghan AD; Seigneux S; Campedel L; Kitchlu A; Shin DS; Rangarajan S; Deshpande P; Coppock G; Eijgelsheim M; Seethapathy H; Lee MD; Strohbehn IA; Owen DH; Husain M; Garcia-Carro C; Bermejo S; Lumlertgul N; Seylanova N; Flanders L; Isik B; Mamlouk O; Lin JS; Garcia P; Kaghazchi A; Khanin Y; Kansal SK; Wauters E; Chandra S; Schmidt-Ott KM; Hsu RK; Tio MC; Sarvode Mothi S; Singh H; Schrag D; Jhaveri KD; Reynolds KL; Cortazar FB; Leaf DE;
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625513
[TBL] [Abstract][Full Text] [Related]
15. Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study.
Yang J; Yuan M; Wang E; Xia S; Chen Y
BMC Ophthalmol; 2019 Nov; 19(1):237. PubMed ID: 31752769
[TBL] [Abstract][Full Text] [Related]
16. Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system.
Li C; Li Z; Sun Q; Xiang Y; Liu A
Expert Opin Drug Saf; 2024 Jun; 23(6):777-784. PubMed ID: 37622438
[TBL] [Abstract][Full Text] [Related]
17. All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.
Vigneau C; Lorcy N; Dolley-Hitze T; Jouan F; Arlot-Bonnemains Y; Laguerre B; Verhoest G; Goujon JM; Belaud-Rotureau MA; Rioux-Leclercq N
Nephrol Dial Transplant; 2014 Feb; 29(2):325-32. PubMed ID: 24302609
[TBL] [Abstract][Full Text] [Related]
18. Contrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective study.
Gökyer A; Küçükarda A; Köstek O; Hacıoğlu MB; Uzunoğlu S; Kula O; Kurt N; Üstündağ S; Erdoğan B; Çiçin İ
Int J Clin Oncol; 2020 Oct; 25(10):1757-1762. PubMed ID: 32591963
[TBL] [Abstract][Full Text] [Related]
19. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.
García M; Palma MB; Verine J; Miriuka S; Inda AM; Errecalde AL; Desgrandchamps F; Carosella ED; Tronik-Le Roux D
BMC Cancer; 2020 Jul; 20(1):624. PubMed ID: 32620162
[TBL] [Abstract][Full Text] [Related]
20. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
